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CASE REPORT
Oseltamivir (Tamiflu) Induced Depressive Episode  
in a Female Adolescent
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Oseltamivir was developed for prophylactic and therapeutic use against influenza, specifically targeting the viral enzyme’s highly-con-
served active site. In recent years, there have been case reports of neuropsychiatric events during or after oseltamivir treatment, in Japan 
and other countries. However, a search of the literature revealed no such cases in South Korea. We present the case of a 15-year-old fe-
male adolescent diagnosed with depressive episode after taking oseltamivir. Oseltamivir is generally well tolerated. Its most frequent ad-
verse effects include nausea and vomiting, diarrhea, and abdominal pain. In influenza patients taking oseltamivir, neuropsychiatric ad-
verse events include delirium, behavioral disturbance, suicide, delusion, panic attack, convulsion, depressed mood, loss of consciousness, 
etc. Reportedly, such neuropsychiatric adverse events were more common in children than in adults and generally occurred within 48 
hours of administration. Here, we report a retrospective review case of an oseltamivir-related neuropsychiatric event in a female adoles-
cent in South Korea.  Psychiatry Investig 2010;7:302-304
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INTRODUCTION
Worldwide, seasonal influenza generally arises each year, 
due to a recombination of the influenza virus.
1 In early April 
2009, the medical community identified the pandemic influ-
enza A (H1N1) virus, which spread rapidly through the world. 
Oseltamivir gained great attention after the onset of the 2009 
pandemic due to the influenza A (H1N1) virus.
2 The drug has 
significant antiviral, biochemical, and clinical effects in human 
influenza virus infections. Oseltamivir is a prodrug of oselta-
mivir carboxylate, a potent and selective inhibitor of neurami-
nidase. Hepatic esterase metabolizes this prodrug to the active 
metabolite, oseltamivir carboxylate, which is not metabolized 
further.
3-5
Oseltamivir was well tolerated, with an adverse effect inci-
dence comparable to that of the placebo recipients in its clini-
cal trials.
6 The most commonly reported adverse effects, in clin-
ical trials of both healthy young adults and high-risk patients, 
were gastrointestinal discomforts, including nausea and vomit-
ing. These generally occurred upon treatment initiation and 
resolved within 2 days. Other adverse effects included diar-
rhea, abdominal pain, epistaxis, ear disorders, rash, swelling of 
the face or tongue, toxic epidermal necrolysis, arrhythmia, diz-
ziness, and conjunctivitis.
5,6 Oseltamivir has no known drug-
drug interactions or adverse events from reported overdoses.
2
Recently, several reports from Japan showed that some os-
eltamivir-treated children had experienced adverse neuropsy-
chiatric events.
2,7,8 More than 100 cases of abnormal behaviors 
and 70 deaths, involving children and adolescents, occurred in 
association with oseltamivir use in Japan.
9 There was a report-
ed case of mania associated with oseltamivir use in a Chinese 
patient.
10 Another report described delirious behavior in pe-
diatric patients following the use of oseltamivir.
11 To estimate 
the incidence rate of adverse neuropsychiatric events in pa-
tients given oseltamivir, Toovey et al.
7 conducted an analysis co-
vering Japan, the US, and other countries and finding such 
neuropsychiatric events generally fell into the categories of 
abnormal behaviors, delusions, and perceptual disturbances. 
In addition, there were cases of delirium and delirium-like ev-
ents, depressed consciousness levels, parasomnia, suicidal ev-
ents, accidents, and injuries. The incidence rate was reported-
ly higher in male than in female patients. Most such events oc-S Chung & YS Joung
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curred within the first 2 days of oseltamivir treatment.
4
A search of the literature revealed few cases of oseltamivir-
induced depressive episodes in South Korea. We present a 
case involving a 15-year-old girl with depressive neuropsychi-
atric symptoms after receiving oseltamivir for the treatment 
of influenza.
CASE
A 15-year-old girl visited our outpatient clinic with symp-
toms of agitation, euphoric mood, flight of ideas, excessive talk-
ing, auditory hallucinations, and decreased need for sleep. She 
was attending an international school in Thailand and had a 
very good record at school.
Looking at her premorbid features, she fulfilled her respon-
sibility for school life and was sincere in every work. She un-
derwent normal development. In a Thailand international 
school, she enjoyed school life and had good relationship with 
friends. Her favorite activities were reading and drawing. She 
could easily concentrate on something and performed good 
academic achievement. She had no family history of mood dis-
order or psychotic disorder.
She had complained of stuffy nose, sore throat, and high fe-
ver symptoms 3 months ago, and she had gone to the hospital 
for a physical examination. At that time, she received a rapid 
diagnostic test for influenza A virus infection. The doctor sus-
pected an influenza A virus infection and prescribed oseltami-
vir for her, as 75 mg of oral oseltamivir, twice daily, for five days. 
Her symptoms improved one day after beginning the medicine.
On her third day taking oseltamivir, the patient became ex-
tremely nervous and had difficulty making decisions. How-
ever, she completed the 5-day oseltamivir treatment. On that 
5th day, she had no need for sleep. She could not sleep at all. 
She was depressed, experienced loss of appetite, and found it 
hard to concentrate on conversation and her schoolwork, such 
as reading books. She experienced a very intense suicidal ide-
ation, reporting that she thought, “How about falling from a 
balcony?”
The patient visited a psychiatry clinic and received a 2-month 
prescription for antidepressants. Subsequently, her mood im-
proved slightly and she could sleep. Her suicidal ideation st-
opped. Therefore, the clinic reduced her antidepressants. A 
week before her visit to our clinic, her aspect became very dif-
ferent. She felt herself to be the most special person. She felt 
very confident, with a greatly elated mood. She was more en-
ergetic than usual, sleeping less and talking more. She thought 
that she understood everything. As the week passed, her symp-
toms worsened, and she began experiencing auditory hallu-
cinations.
The patient visited our psychiatry clinic with the above symp-
toms, accompanied by her mother. We believed she was in a 
manic state and prescribed lithium and antipsychotic drugs: 
150 mg/day lithium and 100 mg/day quetiapine, to start. We 
then increased the drug dosage systematically. Her symptoms 
began to improve within a few days and resolved completely 
after a month. 
DISCUSSION
Oral oseltamivir administration is a known efficacious ther-
apy for influenza in children, when given within 48 hours of 
the illness’s onset. Oseltamivir treatment is generally well tol-
erated, with a low incidence of adverse effect. The most com-
mon adverse effects, nausea and vomiting at the start of treat-
ment, generally are mild to moderate and resolve in 1-2 days. 
In children taking oseltamivir, emesis of mild or moderate in-
tensity and short duration was more frequently reported.
1,2,5,6 
Reportedly, there were also numerous incidences of delirium, 
encephalopathy, abnormal behavior, and other neuropsychi-
atric events after oseltamivir administration.
8,10-12 It seems os-
eltamivir might cause mental instability and suicidal tenden-
cies, and it is critical to determine oseltamivir’s neuropsychia-
tric effects and establish methods for its safe administration.
8,9 
Reportedly, adverse neuropsychiatric events in influenza pa-
tients treated with oseltamivir were more common in children 
and generally occurred within 48 hours of the influenza ill-
ness’s onset and the initiation of treatment. When Toovey et 
al.
7 categorized the reported events per International Classifi-
cation of Diseases (9th edition) codes, abnormal behavior and 
delusions/perceptual disturbances were the largest categories, 
and delirium or delirium-like events were very common with-
in most categories. The abnormal behaviors consisted of hal-
lucinations, delirious speech, frightening episodes, abrupt an-
ger, abnormal overactivity leading to accidents, and putting 
unusual objects into the mouth.
13 Reports from Japan includ-
ed neuropsychiatric behaviors such as adolescents jumping or 
falling from balconies. A large number of these falling or jump-
ing adolescents had no premorbid medical or psychiatric his-
tory indicating a predisposition to such. Many of these cases 
involved adolescents.
9,14 
In the present case, a 15-year-old girl had complained of in-
somnia, agitation, irritability, and impulsive suicidal ideation 
from the 3rd day after oseltamivir administration began. This 
patient developed numerous adverse reactions similar to those 
reported from Japan. She experienced a depressive episode, 
lasting 2 months, after receiving oseltamivir treatment for in-
fluenza. Unfortunately, we did not receive depression scale sc-
ore of her depressive episode from the hospital of Thailand. 
Her school grades greatly dropped below the level she had 
achieved prior to the onset. We thought that she suffered a de-304  Psychiatry Investig 2010;7:302-304
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pressive episode because she had depressive mood, psycho-
motor agitation, irritability, insomnia, diminished ability to 
think or concentrate, recurrent suicidal ideation, and signifi-
cant impairment in social and academic functioning. We did 
not consider that she had a bipolar disorder or major depres-
sive disorder because she didn’t have a family history of bipo-
lar disorder, major depressive disorder, cyclothymic disorder, 
or dysthymic disorder and premorbid episode of mood fluc-
tuation or depressive symptom. But it may be possible that 
her manic symptom was related with antidepressant use. Al-
though it was uncertain, we became assured that her neuro-
psychiatric symptoms were related with the oseltamivir.
After oral administration, oseltamivir is rapidly absorbed 
from the gastrointestinal tract and is then extensively metab-
olized, predominantly by hepatic esterases, into its only ac-
tive metabolite, oseltamivir carboxylate. Oseltamivir carboxy-
late is eliminated by a first-order process, primarily through 
glomerular filtration and renal tubular secretion. Oral oselta-
mivir at 75 mg twice daily, for 5 days, significantly reduces 
the duration of naturally-acquired febrile influenza.
3,4,15,16 
The pharmacological mechanism of the abnormal behav-
iors observed during oseltamivir administration is unknown. 
One study showed increased dopamine metabolism changes 
in the medial prefrontal cortices of rats after systemic oselta-
mivir administration. The researchers reported that oselta-
mivir treatment was correlated with the manifestation of ab-
normal behaviors.
17 Oseltamivir carboxylate can cross the 
BBB from the blood, but one study showed that its active ef-
flux by brain anion transporters limited its brain distribution. 
Therefore, these researchers reported that alterations in an-
ion transporters’ activities would cause inter-individual vari-
ations in exposure to central nervous system and affect the ab-
normal behaviors.
18 Oseltamivir carboxylate facilitates neu-
ronal firing, though this facilitation does not involve GA-
BAergic disinhibition. This suggests that oseltamivir affects 
the central nervous system.
9
However, some researchers suggest it is difficult to distin-
guish the treatment’s effects from those of the disease. Prospec-
tive clinical studies found no evidence of a higher incidence of 
neuropsychiatric events in patients receiving oseltamivir com-
pared to those receiving placebo. These studies support the 
idea that the disease itself, rather than oseltamivir, more likely 
causes such neuropsychiatric events.
7 In the full cohort anal-
ysis, influenza patients receiving oseltamivir experienced no in-
crease in neuropsychiatric claims-based events when compar-
ed to influenza patients who took no antiviral drugs.
12 Research 
will have to resolve this debatable issue.
In this patient, who developed prominent neuropsychiatric 
symptoms immediately after taking oseltamivir, we suggest 
that oseltamivir might increase her potential risk for experi-
encing neuropsychiatric episodes. To our knowledge, this is the 
first reported case of oseltamivir-associated neuropsychiatric 
events in South Korea. Although there are many different ar-
guments, we hope our report will lead clinicians to monitor for 
oseltamivir’s potential neuropsychiatric adverse events.
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